aTyr Pharma, Inc.
NASDAQ Global MarketTotal Valuation
aTyr Pharma, Inc. carries a market capitalization of 33.10M, placing it among publicly traded companies globally. Its enterprise value stands at 12.23M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 33.10M |
| Enterprise Value | 12.23M |
Share Statistics
aTyr Pharma, Inc. currently has 98.09M shares outstanding.
| Shares Outstanding | 98.09M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 307.26, and the price-to-book ratio stands at 1.20.
| PE Ratio | N/A |
| PS Ratio | 307.26 |
| PB Ratio | 1.20 |
| P/TBV Ratio | 1.20 |
| P/FCF Ratio | -1.08 |
| P/OCF Ratio | -1.07 |
Enterprise Valuation
| EV / Sales | 64.35 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
aTyr Pharma, Inc. maintains a current ratio of 5.12, meaning it holds 5.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 5.12 |
| Quick Ratio | 5.08 |
| Debt / Equity | 23.25 |
| Debt / EBITDA | -0.18 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -98.37 |
| Return on Assets (ROA) | -70.97 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
aTyr Pharma, Inc.'s stock has declined approximately -62.20755% over the past 52 weeks. The 50-day moving average sits at 0.48, while the 200-day moving average is 0.67.
| Beta (5Y) | N/A |
| 52-Week Price Change | -62.20755% |
| 50-Day Moving Average | 0.48 |
| 200-Day Moving Average | 0.67 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, aTyr Pharma, Inc. generated 190,000.00 in revenue and converted that into -60.81M in net income, yielding earnings per share of -0.62. EBITDA reached -62.28M, while operating income came in at -63.86M.
| Revenue | 190,000.00 |
| Gross Profit | N/A |
| Operating Income | -63.86M |
| Pretax Income | -60.81M |
| Net Income | -60.81M |
| EBITDA | -62.28M |
| EBIT | -63.86M |
| Earnings Per Share (EPS) | -0.62 |
Balance Sheet
aTyr Pharma, Inc. holds 57.42M in cash and equivalents against 11.30M in total debt, resulting in a net debt position of -16.16M. Total book value stands at 48.79M, with working capital of 46.97M providing operational flexibility.
| Cash & Cash Equivalents | 57.42M |
| Total Debt | 11.30M |
| Net Debt | -16.16M |
| Equity (Book Value) | 48.79M |
| Book Value Per Share | 0.50 |
| Working Capital | 46.97M |
Cash Flow
aTyr Pharma, Inc. produced -54.54M in operating cash flow over the past twelve months. After subtracting -279,000.00 in capital expenditures, free cash flow totaled -54.82M - equivalent to -0.56 per share.
| Operating Cash Flow | -54.54M |
| Capital Expenditures | -279,000.00 |
| Free Cash Flow | -54.82M |
| FCF Per Share | -0.56 |
Margins
aTyr Pharma, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -33,609.47 and net profit margin of -32,003.68 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -33,609.47 |
| Pretax Margin | -32,006.32 |
| Profit Margin | -32,003.68 |
| EBITDA Margin | -32,776.84 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -49.91 |
| FCF Yield | -92.95 |
Stock Splits
aTyr Pharma, Inc.'s most recent stock split took place on July 1, 2019 with a 14:1 split ratio.
| Last Split Date | 7/1/2019 |
| Split Ratio | 14:1 |
Scores
aTyr Pharma, Inc. posts an Altman Z-Score of -13.13, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -13.13 |